Evaluation of the effect of traditional Iranian medicine product on improvement of clinical menifestation of COVID -19

Evaluation of the effect of Traditional medicine product incorporated in the base of Astragalus gossypinus with food spice on improvement of clinical menifestation of COVID -19 patients with conventional protocol

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101219005416N2

Enrollment

Registered

2020-04-03

Start date

2020-03-24

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Confirmed COVID-19

Interventions

Intervention 1: Intervention group: Patients admitted to hospital in addition to receiving standard treatments of the Corona Country Committee, received a traditional product based on Astragalus goss

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients that confirmed COVID- 19 with specialist on the base of CT changing and pharyngeal specimen

Exclusion criteria

Exclusion criteria: Lack of informed consent Pregnancy Breastfeeding

Design outcomes

Primary

Measure	Time frame
Response to the treatment (Significant clinical improvement). Timepoint: At baseline and daily. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), oxygen saturation (> 94% at room temperature) and cough ; dyspnea ; headche and dirrhea that will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.	—

Measure

Time frame

Response to the treatment (Significant clinical improvement). Timepoint: At baseline and daily. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), oxygen saturation (> 94% at room temperature) and cough ; dyspnea ; headche and dirrhea that will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.

—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's medical record.;Mortality. Timepoint: End of the treatment. Method of measurement: Patient's medical record (Clinical outcome).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHaleh Tajadini

Kerman University of Medical Sciences

drhalehtajadini@gmail.com+98 34 3243 5539

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026